

Francois Maisonrouge is the chairman of Evercore's Global Healthcare Group.

At Evercore, among other transactions, Mr. Maisonrouge was involved in advising GSK on its acquisitions of Rapt and of Boston Pharma, Cidara on its sale to Merck, Regulus on its sale to Novartis, Novo Nordisk on its acquisition of manufacturing facilities from Catalent; Takeda on its acquisition of Nimbus; Arena Pharmaceuticals on its sale to Pfizer; Novo Nordisk on its acquisition of Dicerna Pharmaceuticals; Parexel on its sale to EQT; AstraZeneca on its acquisition of Alexion; Sanofi on its acquisition of Principia; Nestlé on its sale of Nestlé Skin Health to EQT and ADIA; Bristol-Myers Squibb on its acquisition of Celgene; Takeda on its acquisition of Shire; AstraZeneca on its defense across from Pfizer; and Sun Pharmaceutical Industries on its acquisition of Ranbaxy Laboratories from Daiichi-Sankyo.

In addition, Mr. Maisonrouge has advised on numerous IPOs and follow-on equity offerings, principally for biotech companies, as well as structured capital raising transactions.

Prior to joining Evercore, Mr. Maisonrouge was a managing director and chairman of life sciences at Credit Suisse.

He is a member of the Board of Advisors of the Harvard Business School Health Care Initiative, and the chairman of the Pasteur Foundation. In 2014, Mr. Maisonrouge was awarded the rank of Chevalier de la Légion d'Honneur.

Mr. Maisonrouge holds an M.S. in engineering from Ecole Centrale de Lyon and an MBA from Harvard Business School.